Palvella Therapeutics (NASDAQ:PVLA) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research report sent to investors on Friday,Benzinga reports. The brokerage currently has a $38.00 price target on the stock.

Separately, Cantor Fitzgerald started coverage on shares of Palvella Therapeutics in a research note on Wednesday, December 18th. They issued an “overweight” rating on the stock.

Palvella Therapeutics Stock Up 10.4 %

NASDAQ:PVLA opened at $13.25 on Friday. The company has a market cap of $17.49 million, a P/E ratio of -1.10 and a beta of 0.61. Palvella Therapeutics has a 1-year low of $6.20 and a 1-year high of $22.32.

Insider Buying and Selling

In other Palvella Therapeutics news, Director George M. Jenkins bought 4,000 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was purchased at an average cost of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the purchase, the director now directly owns 180,671 shares of the company’s stock, valued at approximately $2,336,076.03. This trade represents a 2.26 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 6.39% of the stock is currently owned by company insiders.